TY - JOUR
T1 - Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities
T2 - A MASK-air Study
AU - Vieira, Rafael José
AU - Leemann, Lucas
AU - Briggs, Andrew
AU - Pereira, Ana Margarida
AU - Savouré, Marine
AU - Kuna, Piotr
AU - Morais-Almeida, Mário
AU - Bewick, Michael
AU - Azevedo, Luís Filipe
AU - Louis, Renaud
AU - Klimek, Ludger
AU - Bahbah, Farah
AU - Samolinski, Boleslaw
AU - Anto, Josep M.
AU - Zuberbier, Torsten
AU - Fonseca, João A.
AU - Bousquet, Jean
AU - Sousa-Pinto, Bernardo
AU - Czarlewski, Wienczyslawa
AU - Bedbrook, Anna
AU - Haahtela, Tari
AU - Canonica, G. Walter
AU - Costa, Elisio M.
AU - Kupczyk, Maciej
AU - Kvedariene, Violeta
AU - Kulus, Marek
AU - Larenas-Linnemann, Désirée E.
AU - Pfaar, Oliver
AU - Papadopoulos, Nikolaos G.
AU - Pham-Thi, Nhân
AU - Regateiro, Frederico S.
AU - Roche, Nicolas
AU - Sastre, Joaquin
AU - Scichilone, Nicola
AU - Taborda-Barata, Luis
AU - Valiulis, Arunas
AU - Yorgancioglu, Arzu
AU - Ventura, Maria Teresa
AU - Almeida, Rute
AU - Amaral, Rita
AU - Ansotegui, Ignacio J.
AU - Bergmann, Karl C.
AU - Bosnic-Anticevich, Sinthia
AU - Braido, Fulvio
AU - Brussino, Luisa
AU - Cardona, Victoria
AU - Cecchi, Lorenzo
AU - Loureiro, Claudia Chaves
AU - Cingi, Cemal
AU - Ollert, Markus
AU - MASK-air Think Tank
N1 - Acknowledgments
This work has been made possible due to a partnership among researchers (L. Leemann, J.M. Anto, J. Bousquet, and B. Sousa-Pinto) from the Climate Action To Advance HeaLthY Societies
in Europe (CATALYSE) Project (Grant No. 101057131).
Publisher Copyright:
© 2024 The Authors
PY - 2024/6
Y1 - 2024/6
N2 - Background: Allergic rhinitis (AR) and asthma may affect health-related quality of life. However, national estimates on the quality of life of patients with AR or asthma are lacking. Objective: To provide estimates for utility scores and EuroQoL five-dimension (EQ-5D) visual analog scale (VAS) for patients with AR or asthma. Methods: We conducted a cross-sectional study using direct patient data from the MASK-air app on European MASK-air users with self-reported AR or asthma. We used a multi-attribute instrument (EQ-5D) to measure quality of life (as utility scores and EQ-5D VAS values). Mean scores were calculated per country and disease control level using multilevel regression models with poststratification, accounting for age and sex biases. Results: We assessed data from 7905 MASK-air users reporting a total of up to 82,737 days. For AR, utilities ranged from 0.86 to 0.99 for good control versus 0.72 to 0.85 for poor control; EQ-5D VAS levels ranged from 78.9 to 87.9 for good control versus 55.3 to 64.2 for poor control. For asthma, utilities ranged from 0.84 to 0.97 for good control versus 0.73 to 0.87 for poor control; EQ-5D VAS levels ranged from 68.4 to 81.5 for good control versus 51.4 to 64.2 for poor control. Poor disease control was associated with a mean loss of 0.14 utilities for both AR and asthma. For the same control levels, AR and asthma were associated with similar utilities and EQ-5D VAS levels. However, lower values were observed for asthma plus AR compared with AR alone. Conclusions: Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.
AB - Background: Allergic rhinitis (AR) and asthma may affect health-related quality of life. However, national estimates on the quality of life of patients with AR or asthma are lacking. Objective: To provide estimates for utility scores and EuroQoL five-dimension (EQ-5D) visual analog scale (VAS) for patients with AR or asthma. Methods: We conducted a cross-sectional study using direct patient data from the MASK-air app on European MASK-air users with self-reported AR or asthma. We used a multi-attribute instrument (EQ-5D) to measure quality of life (as utility scores and EQ-5D VAS values). Mean scores were calculated per country and disease control level using multilevel regression models with poststratification, accounting for age and sex biases. Results: We assessed data from 7905 MASK-air users reporting a total of up to 82,737 days. For AR, utilities ranged from 0.86 to 0.99 for good control versus 0.72 to 0.85 for poor control; EQ-5D VAS levels ranged from 78.9 to 87.9 for good control versus 55.3 to 64.2 for poor control. For asthma, utilities ranged from 0.84 to 0.97 for good control versus 0.73 to 0.87 for poor control; EQ-5D VAS levels ranged from 68.4 to 81.5 for good control versus 51.4 to 64.2 for poor control. Poor disease control was associated with a mean loss of 0.14 utilities for both AR and asthma. For the same control levels, AR and asthma were associated with similar utilities and EQ-5D VAS levels. However, lower values were observed for asthma plus AR compared with AR alone. Conclusions: Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.
KW - Allergic rhinitis
KW - Asthma
KW - EQ-5D-5L
KW - Health-related quality of life
KW - Mobile health
KW - Quality of life
KW - Real-world data
KW - Utilities
UR - http://www.scopus.com/inward/record.url?scp=85189520751&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38561141
U2 - 10.1016/j.jaip.2024.03.036
DO - 10.1016/j.jaip.2024.03.036
M3 - Article
C2 - 38561141
AN - SCOPUS:85189520751
SN - 2213-2198
VL - 12
SP - 1530-1538.e6
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -